Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1801–1824 of 22,226 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: control 2 Clear all

Conditions: Surgical Site Infection
Interventions: IrriSept System, No Intervention - Standard of Care (SoC) only; Device · Other
Lead sponsor: Irrimax Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 627 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 17
States / cities: Tucson, Arizona • Los Angeles, California • Denver, Colorado + 14 more

Conditions: Liver Transplant Rejection
Interventions: CFZ533, Tacrolimus - MMF - corticosteroids; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 9
States / cities: Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 6 more

Conditions: HIV-1 Infection
Interventions: Islatravir, Ulonivirine, BIC/FTC/TAF, Placebo to ISL, Placebo to Ulonivirine, Placebo to BIC/FTC/TAF; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 10
States / cities: Phoenix, Arizona • Los Angeles, California • Ft. Pierce, Florida + 7 more

Conditions: Tobacco Use Cessation
Interventions: Varenicline plus Motivational Interviewing counseling, Varenicline without counseling; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 428 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Headache, Pregnancy Related, Occipital Nerve Block
Interventions: Occipital Nerve Block; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 16 Years to 60 Years · Female only
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Low Back Pain
Interventions: Core Stabilization; Other
Lead sponsor: Drexel University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • West Chester, Pennsylvania

Conditions: Shoulder Pain, Neck Pain
Interventions: Noxipoint Therapy, Physical Therapy; Procedure
Lead sponsor: Pain Cure Center, California; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Post-Traumatic Stress Symptoms, Problematic Use of Alcohol or Other Drugs
Interventions: Web-based Cognitive Behavioral Treatment; Behavioral
Lead sponsor: National Development and Research Institutes, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 2
States / cities: Buffalo, New York • Syracuse, New York

Conditions: Diabetic Neuropathies
Interventions: SSR180575, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Overweight, Obese
Interventions: Decrease Energy Density of the Diet, Increase Steps per Day, Consumption of Self-made Meals; Behavioral
Lead sponsor: The University of Tennessee, Knoxville; Other
Eligibility: 18 Years to 35 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Heart Failure
Interventions: HNO Donor, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 24
States / cities: Tucson, Arizona • Gainesville, Florida • Tampa, Florida + 16 more

Conditions: Stress Disorder
Interventions: Guanfacine Extended Release, Mindfulness Skills Therapy, Placebo; Drug · Behavioral
Lead sponsor: UConn Health; Other
Eligibility: 10 Years to 20 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Tuberous Sclerosis
Interventions: Parent-Child Interaction Therapy (PCIT); Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 3 Years to 6 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Rheumatoid Arthritis
Interventions: AMP-110, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 7
States / cities: Anniston, Alabama • Orlando, Florida • Palm Harbor, Florida + 4 more

Conditions: Moderate to Severe Convexity of Submental Fat, Safety, Efficacy
Interventions: ATX-101, Placebo; Drug
Lead sponsor: Kythera Biopharmaceuticals; Industry
Eligibility: 65 Years to 75 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 6
States / cities: Birmingham, Alabama • Los Angeles, California • Bradenton, Florida + 3 more

Conditions: Colitis, Ulcerative
Interventions: ST-0529; Drug
Lead sponsor: Sublimity Therapeutics Holdco Limited; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 8
States / cities: Palm Springs, California • Largo, Florida • New Port Richey, Florida + 4 more

Conditions: 22q11 Deletion Syndrome
Interventions: NB-001, Placebo; Drug · Other
Lead sponsor: Nobias Therapeutics, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Aurora, Colorado • Philadelphia, Pennsylvania • Seattle, Washington

Conditions: Non-Eosinophilic Asthma
Interventions: AVTX-002, Placebo; Drug
Lead sponsor: Avalo Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 24
States / cities: Tucson, Arizona • Sacramento, California • Walnut Creek, California + 20 more

Conditions: Patient Safety, Organizational Change
Interventions: Simulate a functional NICU prior to moving patients; Other
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: Not listed
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Chronic Pain, Social Disconnection
Interventions: Artwork present, Artwork absent, Social connection high, Social connection low; Behavioral
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 311 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions: VX-407, Placebo, Midazolam; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 159 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Hypertension, Hypotension, Edema, Congestive Heart Failure
Interventions: furosemide, placebo; Drug
Lead sponsor: University of Calgary; Other
Eligibility: 18 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Menopause
Interventions: Placebo, S-equol; Drug
Lead sponsor: Ausio Pharmaceuticals, LLC; Industry
Eligibility: Female only
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 5
States / cities: Louisville, Kentucky • Cincinnati, Ohio • Cleveland, Ohio + 2 more

Conditions: Primary Hyperparathyroidism, Type 2 Diabetes
Interventions: Urine and Blood Test; Diagnostic Test
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

Irrisept Versus Standard of Care in the Prevention of Surgical Site Infections

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension

Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]

Improving Varenicline Adherence and Outcomes in Homeless Smokers

Acute Headache Treatment in Pregnancy: Occipital Nerve Block vs PO Acetaminophen With Caffeine

Clinical Prediction Rule for Clinical Lumbar Instability

Noxipoint Therapy Versus Standard Physical Therapy Using Electrical Stimulation for Chronic Pain

Web-based CBT for Recent Veterans Experiencing Problems With Trauma Symptoms or Alcohol/Drug Use

Dose-effect of SSR180575 in Diabetic Neuropathy

Foundations for Health

Evaluate the Safety and Efficacy of 48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart Failure

Guanfacine Extended Release and Mindfulness Skills Therapy

Remote Assessment and Intervention for Behavior Problems in Kids With TSC

Assess Safety, Tolerability, Pharmacokinetics and Clinical Activity of AMP-110 in Subjects With Rheumatoid Arthritis

Safety Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of Age

A Study Evaluating the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis

NB-001 in Children and Adolescents With 22q11 Deletion Syndrome

A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.

Generalizing TESTPILOT to New Single Family Room NICUs

Can Exposure to Inclusive Virtual Art Decrease Pain and Social Disconnection Among Individuals Living With Chronic Pain?

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants

Trial Assessing the Effect of Preoperative Furosemide on Intraoperative Blood Pressure

Efficacy and Safety of S-equol on Vasomotor Symptoms in Menopausal Patients

Glycemic Control, Type II Diabetes, Parathyroidectomy